Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
Status:
Enrolling by invitation
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the safety and tolerability of ATH-1017 in
subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized
treatment in Study ATH-1017-AD-0201 or Study ATH-1017-AD-0202.